Exyte increases orders, sales and profitability

  • New orders are up more than 25% year-on-year, marking a new level 9M-high with €6.5 billion

  • Sales volume increased by almost 60% to €5.3 billion

  • Strong increase in sales in all three business areas

  • Adjusted EBIT increased by 73% to €308 million; Adjusted EBITDA increased by 70% to €340 million

  • Acquisition of Airgard Inc., expansion of the strategic product portfolio of the technology and service business

  • New employer brand to attract new talent

STUTTGART, Germany, November 9, 2022 /PRNewswire/ — Exyte GmbH (Exyte), a global leader in the design, engineering and supply of high-tech assets, successfully continues its strong performance in the first nine months of fiscal year 2022 on its accelerated growth path, its “Pathway to Ten”.



In the first nine months of 2022, Exyte reported a nearly 60% year-over-year increase in revenue. Sales reached an all-time high of €5.3 billion (9M/2021: €3.4 billion) through major projects in all business areas, particularly in the APAC and EMEA regions. Both regions also made a strong contribution to order intake. From January to September, incoming orders reached €6.5 billion (9M/2021: €5.1 billion), an increase of more than 25% compared to the previous year.

With an adjusted EBITDA of €340 million (9M/2021: €200 million) and an adjusted EBIT of €308 million (9M/2021: €178 million) Exyte has further improved its profitability. Adjusted EBITDA margin was 6.4% (9M/2021: 5.9%), the adjusted EBIT margin reached 5.8% (9M/2021: 5.3%), each 0.5 percentage points better than in the previous year.

“Our sustained positive business development underscores our strong strategic position. The industries we serve continue to invest. Despite the current global economic development, we do not expect any major setbacks for these sectors or for our business. We serve global megatrends that will continue to unfold despite short-term economic turbulence,” says Dr. Wolfgang Büchele, CEO of Exyte.

Positive outlook despite current economic developments

“Exyte is successful on its ‘Pathway to Ten’. Our sales target of around 7 billion euros in 2022 brings us closer to our goal of reaching 10 billion euros in sales in 2027. With successfully running projects and an order backlog of 8.2 billion euros, we are well positioned for future profitable growth and, despite the ongoing economic uncertainties, we see a sustainable positive development for Exyte,” says Peter Schönhofer, CFO of Exyte. “We are monitoring developments and their potential impact on our business and take countermeasures where necessary.”

Exyte confirms the positive year-end outlook. A corresponding increase in adjusted EBITDA and adjusted EBIT is expected in line with an increase in sales. For 2022, the company forecasts adjusted EBITDA of around EUR 450 million and adjusted EBIT of over EUR 400 million.

Growth across all businesses, Biopharma & Life Sciences and Data Centers with impressive revenue development

In the first nine months of 2022, all three business segments acquired substantial new projects in all regions. With a sales share of around 87% of the total sales of the group, the business area Advanced technology facilities recorded an increase in sales of around 55% to €4.6 billion (9M/2021: €3.0 billion). Driven by the continued positive development of the semiconductor industry, incoming orders rose by almost a quarter to €5.5 billion (9M/2021: €4.5 billion). Battery cell manufacturers also benefit from Exyte’s expertise in clean and dry rooms. Exyte sees further sales opportunities in this business in the coming years, as so-called gigafabs for the production of battery cells and batteries are planned worldwide.

Biopharma & Life Sciences Sales almost doubled in the first nine months. Segment sales reached €477 million (9M/2021: €247 million) due to major projects in Singapore and Malaysia. Biopharma & Life Sciences accounts for 9.0% of total Group sales (9M/2021: 7.3%). Order intake reached €477 million (9M/2021: €384 million). in the GermanyExyte is building an mRNA competence center in Halle. Further biopharma projects for global pharmaceutical companies are currently being prepared. Exyte recently opened a new Life Sciences Office in Cork, Ireland. The Irish pharmaceutical sector has grown rapidly in recent years. Exyte anticipates significant investment in Ireland in projects ranging from biotechnology to fill finish, active pharmaceutical ingredients and cell and gene therapy.

Selling the data center Segment increased by 74% to €181 million (9M/2021: €104 million). Order intake increased by more than 130% to €409 million (9M/2021: €175 million). The division is currently realizing data center projects in Austria, Denmark, Germany, Israel, Malaysiaand Taiwanamong other things.

Strategic growth of the Technology and Services segment

Exyte recently completed the acquisition of Airgard Inc., a US-based emissions control technology specialist. Airgard’s wet scrubbers are used by key players in the semiconductor industry worldwide. The acquisition of Airgard strengthens Exyte’s position to support its customers with technical solutions for their emissions management, also in view of the increasing standards that come with environmental, social and governance (ESG) regulations and requirements.

This is the next acquisition as Exyte builds on its vertical integration strategy by strengthening its business in mission-critical technologies and services. In 2021, Exyte acquired the Critical Process Systems Group and made it part of the Technology & Services (T&S) business. T&S consists of companies that provide cleanroom technology, installation services and critical equipment for its customers’ subsystems, as well as off-site manufacturing (OSM). In the first nine months of 2022, Technology & Services almost doubled sales to €555 million (9M/2021: €280 million) contribute around 10% to the total sales of the group (9M/2021: 8.0%). Order intake more than doubled to €788 million (9M/2021: €336 million).

Progress on the “Pathway to Ten” – New Employer Branding

Targeted, strategic acquisitions are a cornerstone of Exyte’s “Next Level” future agenda. In it, the company has defined several fields of action in order to be successful on its “Pathway to Ten”. Another field of action is to become the employer of choice for existing and future employees. Exyte recently introduced a new employer brand that forms the basis for global talent acquisition and recruitment. Around 15,000 employees are expected to work for Exyte in 2027, more than twice as many as in 2021 Sep 2022 Exyte employs nearly 9,000 people worldwide.

Financial figures at a glance




2022 vs 2021

incoming orders

€6.5 billion

€5.1 billion



€5.3 billion

€3.4 billion


Adjusted EBITDA

€340 million

€200 million


Adjusted EBITDA margin



+0.5 PP

Adjusted EBIT

€308 million

€178 million


Adjusted EBIT margin



+0.5 PP

*The percentage is calculated from the values ​​in millions.

For more details about the 9M-Results 2022 can be found on the website exyte.net.

About Exyte

Exyte is a global leader in the design, engineering and supply of ultra-clean and sustainable systems for high-tech industries. With cutting-edge expertise developed over more than a century, we serve customers in the demanding semiconductor, battery cell, pharmaceutical, biotechnology and data center markets. Exyte offers our customers worldwide a full range of services from consulting to managing the implementation of turnkey solutions with the highest safety and quality standards. We create a better future by enabling key industries to improve the quality of modern life. In 2021, Exyte generated sales of 4.9 billion euros with around 7,400 employees worldwide.


Rene Ziegler
Vice President Corporate Communications & Investor Relations
+49 711 88044606
+49 172 5838786
[email protected]

Logo: https://mma.prnewswire.com/media/1487100/Exyte_Logo.jpg



View original content: https://www.prnewswire.co.uk/news-releases/strong-business-performance-in-9m2022-exyte-increases-order-intake-sales-and-profitability-301672765.html


Leave a Reply

Your email address will not be published. Required fields are marked *